• Nutramigen LGG:

    4 Weeks - Results in 0% blood in stools after 4 weeks of feeding.

    6 Months - Helps infants consume milk protein without anallergic response in as early as 6 months of feeding.

    12 Months - Helps more infants quickly return to cow's milk than other formula options

    3 Years - Reduces the likelihood of other allergic manifestations by 50% at 3 years.

    * LGG is a registered trademark of Valio Ltd.
    † Rhinoconjunctivitis, urticaria, eczema and asthma.
    ‡ When managing colic due to cow’s milk allergy.
    § Studied before the addition of DHA, ARA or LGG.


    New Data!

    Nutramigen LGG* can help reduce the incidence of allergic manifestations

    "Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial”

    Canani RB et al. J Allergy Clin Immunol. 2017. doi: http://dx.doi.org/10.1016/j.jaci.2016.10.050. (In press.)

    50% reduction in the likelihood of other allergic manifestatations

    STUDY OBJECTIVES

    To determine whether an extensively hydrolyzed casein formula (EHCF) with the probiotic Lactobacillus rhamnosus GG (LGG) could reduce the occurrence of other allergic manifestations in children with cow’s milk allergy (CMA).

    STUDY DESIGN

    This parallel-arm randomized controlled trial included 220 children with IgE-mediated CMA who were randomly allocated to either an EHCF or EHCF+LGG group and followed for 36 months. Children were evaluated for allergic manifestations (eczema, rhinoconjunctivitis, urticaria and asthma).

    RESULTS

    Incidence of allergic manifestations within the 36 months in the EHCF group was 46.3%, while the EHCF+LGG group was only 23.5%. The EHCF+LGG reduced the likelihood of other allergic manifestations by ~50%.

    Further analysis suggests, when manifestations were assessed individually, infants with CMA experienced:

    68% reduction in rhinoconjunctivitis61% reduction in allergic urticaria44% reduction in eczema51% reduction in asthma

    Download Full Study

    * LGG is a registered trademark of Valio Ltd.
    † Rhinoconjunctivitis, urticaria, eczema and asthma.
    ‡ Reduction in these individual manifestations did not reach statistical significance.


    Nutramigen LGG* helps infants return to milk protein in as early as 6 months of feeding

    “Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: A randomized trial”

    Canani RB et al. J Allergy Clin Immunol. 2012;129:580-582.

    STUDY OBJECTIVE

    To evaluate the effectiveness of the probiotic Lactobacillus rhamnosus GG (LGG) in helping infants with cow’s milk allergy (CMA) consume milk protein without an allergic response.

    STUDY DESIGN

    This randomized controlled open trial included infants with confirmed CMA who were randomly assigned to either an extensively hydrolyzed casein formula (EHCF) or EHCF+LGG group. Infants were tested after 6 and 12 months of feeding to determine if tolerance to milk protein was reached.

    RESULTS

    At 6 months follow-up, 59% of infants in the EHCF+LGG group were tolerant to milk protein, compared to 21% in the EHCF group. At 12 months follow-up, 81% of infants fed EHCF+LGG had achieved tolerance to milk protein compared to 54% in the EHCF group.

    After 6 months of feeding Nutramigen LGG, 59% of infants could consume cow’s milk protein

     

    Infants were able to consume 1 cup of cow's milk daily without signs of allergy

    Download Full Study

    * LGG is a registered trademark of Valio Ltd.


    Nutramigen LGG* helps more infants consume milk protein than other formulas studied

    “Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: A prospective multicenter study”

    Canani RB et al. J Pediatr. 2013;163:771-777.

     

    STUDY OBJECTIVES

    To compare the number of infants with cow’s milk allergy (CMA) able to consume milk protein without an allergic response after 12 months of consuming an extensively hydrolyzed casein formula (EHCF) with the probiotic Lactobacillus rhamnosus GG (LGG) vs. other formula options.

    STUDY DESIGN

    This prospective, multicenter study included 260 infants with confirmed CMA who were divided into 5 groups based upon the formula consumed at study entry: extensively hydrolyzed casein formula (EHCF), EHCF+LGG, hydrolyzed rice formula, soy formula or amino acid-based formula. Children were tested after 12 months of feeding to determine if they could consume milk protein without an allergic response.

    RESULTS

    79% of infants fed EHCF+LGG could consume milk protein after 12 months of feeding. This result was at least 80% higher than any other formula used in the study.

    Significantly more infants could consume cow’s milk protein after 1 year of feeding Nutramigen LGG (P<0.05)

     

    Comulative at 12 months

    Download Full Study

    * LGG is a registered trademark of Valio Ltd.
    † Compared to other formulas used in the study. Formulas included: extensively hydrolyzed casein: Nutramigen and Nutribén hydrolyzed®; rice hydrolysate: Risolac®; soy: Isomil®, Sinelac®, Nutrilon Soya®; amino acid: Neocate®, Nutramigen AA®, Sineall®.


    Nutramigen LGG* significantly improves occult blood in stools

    “Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone”

     

    Baldassarre ME et al. J Pediatr. 2010;156:397-401.

     

    STUDY OBJECTIVE

    To determine the effectiveness of the probiotic LGG in an extensively hydrolyzed casein formula (EHCF) compared to EHCF alone in improving blood in stools and level of fecal calprotectin, a marker of intestinal inflammation, in infants with suspected cow’s milk allergy (CMA).

    STUDY DESIGN

    Sixty-two infants aged 1-10 months were enrolled in the study; group A included 30 infants with suspected CMA and group B, the comparison group, included 32 healthy infants of same sex and age. Formula-fed infants in group A underwent a randomized, double-blind placebo-controlled assignment to either EHCF with the probiotic LGG (EHCF+LGG) or EHCF without the probiotic LGG. Infants in group B made no changes to their feeding. Both groups were evaluated for occult blood in stools and level of fecal calprotectin at enrollment and after 4 weeks.

    RESULTS

    At 4 weeks, infants fed EHCF+LGG had significantly larger decreases in level of fecal calprotectin than those fed EHCF. Infants in the EHCF+LGG group also had 0% occult blood in stools after 4 weeks of feeding

     

    Feeding Nutramigen LGG resulted in 0% blood in stool after 4 weeks of feeding

    Download Full Study

    * LGG is a registered trademark of Valio Ltd.


    References:
    1. Lothe L et al. Pediatrics. 1989;83:262-266.
    2. Baldassarre ME at al. J Pediatr. 2010;156:397-401.
    3. Canani RB et al. J Allergy Clin Immunol. 2012;129:580-582.
    4. Canani RB et al. J Pediatr. 2013;163:771-777.
    5. Canani RB et al. J Allergy Clin Immunol. 2017. doi: http://dx.doi.org/10.1016/j.jaci.2016.10.050. (In press.)
    6. Canani RB, email, April 23, 2012.